OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CML

December 15th 2020

Gaby Hobbs, MD, discusses managing ponatinib-associated toxicities in chronic myeloid leukemia.

Dr. Atkins on the Benefits of Neoadjuvant Therapy in Melanoma

December 15th 2020

Michael B. Atkins, MD, discusses the benefits of neoadjuvant therapy in melanoma.

Dr. Sweet on Treatment Selection With TKIs in CML

December 15th 2020

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

Dr. Sullivan on Treatment Options in BRAF-Mutant Melanoma

December 15th 2020

Ryan Sullivan, MD, discusses treatment options in BRAF-mutant melanoma.

Dr. Cavnar on Surgical Differences Between Right- and Left-Sided Tumors in CRC

December 15th 2020

Michael J. Cavnar, MD, discusses surgical differences between right- and left-sided tumors in colorectal cancer.

Dr. Pandalai on the Development of Peritoneal Carcinomatosis in CRC

December 15th 2020

Prakash Pandalai, MD, discusses the development of peritoneal carcinomatosis in colorectal cancer.

Dr. Pandalai on the Use of Cytoreductive Surgery Plus HIPEC in Colorectal Peritoneal Carcinomatosis

December 15th 2020

Prakash Pandalai, MD, discusses the use of cytoreductive surgery plus heated intraperitoneal chemotherapy in the treatment of patients with colorectal peritoneal carcinomatosis.

Dr. Wang on Preliminary Findings From the KOMET-001 Trial in Relapsed/Refractory AML

December 15th 2020

Eunice Wang, MD, discusses preliminary findings from the ongoing KOMET-001 trial in relapsed/refractory acute myeloid leukemia.

Dr. Powles on the Role of ctDNA Positivity in High-Risk Muscle-Invasive Urothelial Cancer

December 15th 2020

Thomas Powles, MBBS, MRCP, MD, discusses the role of circulating tumor DNA positivity in high-risk muscle-invasive urothelial cancer.

Dr. Pusztai on the Role of ctDNA as a Biomarker in Breast Cancer

December 15th 2020

Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.

Dr. DeAngelo on the Mechanism of Action of Pevonedistat in MDS

December 15th 2020

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of pevonedistat in myelodysplastic syndrome.

Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma

December 14th 2020

Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.

Dr. Weber on the Toxicities Associated With Immunotherapy in Lung Cancer

December 14th 2020

Jeffrey S. Weber, MD, PhD, discusses the toxicities associated with immunotherapy in lung cancer.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Grothey on Investigational Combinations in MSI-High CRC

December 11th 2020

Axel Grothey, MD, discusses investigational combination therapies in microsatellite instability–high colorectal cancer.

Dr. Weber on Unmet Needs in Melanoma

December 9th 2020

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

Dr. Stadtmauer on the Evolving Treatment Landscape in Multiple Myeloma

December 9th 2020

Edward A. Stadtmauer, MD, discusses the evolving treatment landscape in multiple myeloma.

Dr. Spivak on Diagnosing Essential Thrombocythemia

December 9th 2020

Jerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Dr. Coffman on the Role of Targeted Therapy in TNBC

December 9th 2020

Lan G. Coffman, MD, PhD, discusses the role of targeted therapy in triple-negative breast cancer.